ARCUTIS BIOTHERAPEUTICS, INC. Operating Expenses
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Operating Expenses of $75.01 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2023-11-03
- ARCUTIS BIOTHERAPEUTICS, INC. operating expenses for the quarter ending 2023-09-30 was $75.01M, a 28.88% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. operating expenses for the quarter ending 2023-06-30 was $71.95M, a 9.31% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. operating expenses for the quarter ending 2023-03-31 was $79.05M, a 26.22% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. operating expenses for the quarter ending 2022-12-31 was $71.39M, a 0.14% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. operating expenses for fiscal 2022 was $305.31M, a 47.83% increase from fiscal 2021.
- ARCUTIS BIOTHERAPEUTICS, INC. operating expenses for fiscal 2021 was $206.53M, a 51.14% increase from fiscal 2020.
- ARCUTIS BIOTHERAPEUTICS, INC. operating expenses for fiscal 2020 was $136.65M, a 216.81% increase from fiscal 2019.
- ARCUTIS BIOTHERAPEUTICS, INC. operating expenses for fiscal 2019 was $43.13M, a 118.56% increase from fiscal 2018.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2023-09-30 | $75.01M 10-Q · filed 2023-11-03 | $146.97M derived: sum of 2 quarters · filed 2023-11-03 | $226.01M 10-Q · filed 2023-11-03 | $297.40M derived: sum of 4 quarters · filed 2023-11-03 |
| 2023-06-30 | $71.95M 10-Q · filed 2023-08-08 | $151.00M 10-Q · filed 2023-08-08 | $222.38M derived: sum of 3 quarters · filed 2023-08-08 | $327.86M derived: sum of 4 quarters · filed 2023-11-03 |
| 2023-03-31 | $79.05M 10-Q · filed 2023-05-09 | $150.43M derived: sum of 2 quarters · filed 2023-05-09 | $255.90M derived: sum of 3 quarters · filed 2023-11-03 | $321.73M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-12-31 | $71.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $176.86M derived: sum of 2 quarters · filed 2023-11-03 | $242.69M derived: sum of 3 quarters · filed 2023-11-03 | $305.31M 10-K · filed 2023-02-28 |
| 2022-09-30 | $105.47M 10-Q · filed 2023-11-03 | $171.30M derived: sum of 2 quarters · filed 2023-11-03 | $233.93M 10-Q · filed 2023-11-03 | $305.21M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $65.83M 10-Q · filed 2023-08-08 | $128.46M 10-Q · filed 2023-08-08 | $199.74M derived: sum of 3 quarters · filed 2023-08-08 | $256.82M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $62.63M 10-Q · filed 2023-05-09 | $133.91M derived: sum of 2 quarters · filed 2023-05-09 | $190.99M derived: sum of 3 quarters · filed 2023-05-09 | $233.07M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $71.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $128.36M derived: sum of 2 quarters · filed 2023-02-28 | $170.44M derived: sum of 3 quarters · filed 2023-02-28 | $206.53M 10-K · filed 2023-02-28 |
| 2021-09-30 | $57.08M 10-Q · filed 2022-11-08 | $99.16M derived: sum of 2 quarters · filed 2022-11-08 | $135.24M 10-Q · filed 2022-11-08 | $169.31M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $42.08M 10-Q · filed 2022-08-04 | $78.17M 10-Q · filed 2022-08-04 | $112.23M derived: sum of 3 quarters · filed 2022-08-04 | $150.53M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $36.09M 10-Q · filed 2022-05-05 | $70.15M derived: sum of 2 quarters · filed 2022-05-05 | $108.45M derived: sum of 3 quarters · filed 2022-05-05 | $144.08M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $34.06M 10-K · filed 2021-02-16 | $72.37M derived: sum of 2 quarters · filed 2021-11-04 | $107.99M derived: sum of 3 quarters · filed 2021-11-04 | $136.65M 10-K · filed 2023-02-28 |
| 2020-09-30 | $38.30M 10-Q · filed 2021-11-04 | $73.93M derived: sum of 2 quarters · filed 2021-11-04 | $102.58M 10-Q · filed 2021-11-04 | $115.58M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $35.63M 10-Q · filed 2021-08-05 | $64.28M 10-Q · filed 2021-08-05 | $77.27M derived: sum of 3 quarters · filed 2021-08-05 | $91.92M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $28.65M 10-Q · filed 2021-05-06 | $41.65M derived: sum of 2 quarters · filed 2021-05-06 | $56.29M derived: sum of 3 quarters · filed 2021-05-06 | $64.83M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $12.99M 10-K · filed 2021-02-16 | $27.64M derived: sum of 2 quarters · filed 2021-02-16 | $36.18M derived: sum of 3 quarters · filed 2021-02-16 | $43.13M 10-K · filed 2022-02-22 |
| 2019-09-30 | $14.65M 10-K · filed 2021-02-16 | $23.19M derived: sum of 2 quarters · filed 2021-02-16 | $30.14M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $8.54M 10-K · filed 2021-02-16 | $15.49M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $6.95M 10-K · filed 2021-02-16 | |||
| 2018-12-31 | $19.73M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |